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ABSTRACT 
Peroxiredoxins are ubiquitous proteins that catalyze the reduction of hydroperoxides, thus 
conferring resistance to oxidative stress. Using high-resolution mass spectrometry, we 
recently re-classified one such peroxiredoxin, bacterioferritin comigratory protein (BCP) of 
Escherichia coli, as an atypical 2-Cys peroxiredoxin that functions through the formation of 
an intramolecular disulfide bond between the active and resolving cysteine. An engineered E. 
coli BCP, which lacked the resolving cysteine, retained enzyme activity through a novel 
catalytic pathway. Unlike the active cysteine, the resolving cysteine of BCP peroxiredoxins is 
not conserved across all members of the family. To clarify the catalytic mechanism of native 
BCP enzymes that lack the resolving cysteine, we have investigated the BCP homologue of 
Burkholderia cenocepacia. We demonstrate that the B. cenocepacia BCP (BcBCP) 
homologue functions through a 1-Cys catalytic pathway. During catalysis, BcBCP can utilize 
thioredoxin as a reductant for the sulfenic acid intermediate. However, significantly higher 
peroxidase activity is observed utilizing glutathione as a resolving cysteine and glutaredoxin 
as a redox partner. Introduction of a resolving cysteine into BcBCP changes the activity from 
a 1-Cys pathway to an atypical 2-Cys pathway, analogous to the E. coli enzyme. In contrast to 
the native B. cenocepacia enzyme, thioredoxin is the preferred redox partner for this atypical 
2-Cys variant. BCP-deficient B. cenocepacia exhibit a growth-phase dependent 
hypersensitivity to oxidative killing. Based on sequence alignments, we believe that BcBCP 
described herein is representative of the major class of bacterial BCP peroxiredoxins. To our 
knowledge, this is the first detailed characterization of their catalytic activity. These studies 
support the subdivision of the BCP family of peroxiredoxins into two classes based on their 
catalytic activity. 
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Reactive oxygen species (ROS) arising from the incomplete reduction of oxygen are an 
inevitable consequence of aerobic metabolism, and result in wide-ranging oxidative damage 
to nucleic acids, proteins and lipids. Organisms occupying aerobic environments have evolved 
numerous reductive defense mechanisms against ROS. Peroxiredoxins (Prxs), which 
undertake the thiol-dependent reduction of peroxide substrates, constitute one such 
defense mechanism. The catalytic activity of Prxs can be divided into 1-Cys and 2-Cys 
pathways based on the number of cysteines required for catalysis. The 2-Cys Prxs are further 
divided into typical and atypical 2-Cys peroxidases; typical 2-Cys Prxs being obligate dimers, 
whilst atypical 2-Cys Prxs are monomeric. During the reduction of hydroperoxides, all Prxs 
share a common first step, which involves an active (peroxidatic) cysteine thiolate attacking 
the peroxide substrate resulting in the formation of a sulfenic acid (Cys-SOH) intermediate on 
the active cysteine. Thereafter, different pathways may be employed in the resolution of the 
sulfenic acid intermediate, and it is variation in this process which leads to the delineation of 
the Prxs into 1-Cys and 2-Cys peroxidases (1). 2-Cys Prxs contain a second cysteine, termed 
the resolving cysteine, which attacks the sulfenic acid intermediate of the active cysteine, 
forming a disulfide bond that is subsequently reduced by a cell-specific oxidoreductase. The 
disulfide bond between the active and resolving cysteine can be either intramolecular 
(monomeric atypical 2-Cys pathway) or intermolecular (dimeric typical 2-Cys). In contrast, 1-
Cys Prxs do not harbour a resolving cysteine. In this case, the sulfenic acid intermediate is 
thought to be resolved by thiol-containing reductants such as glutathione or thioredoxin. 
The bacterioferritin comigratory protein (BCP) family of Prxs was first characterized in 
Escherichia coli (2). BCP is a monomeric protein with thiol-dependent peroxidase activity, 
which until recently was assumed to function via a 1-Cys mechanism, based on observations 
made of the E. coli enzyme. However, by applying high-resolution mass spectrometry, we 
recently reclassified E. coli BCP (EcBCP) as an atypical 2-Cys enzyme, functioning via the 
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formation of an intramolecular disulfide bond between an active and resolving cysteine (3). 
Sequence alignments of prokaryotic BCP homologues revealed that the majority of 
homologues lack the resolving cysteine, and as such would be expected to function via a 1-
Cys catalytic process. However, an engineered EcBCP, in which the resolving cysteine was 
replaced with a serine (C50S), retained peroxidatic activity through a novel catalytic 
mechanism distinct from the anticipated 1-Cys pathway (3).  
BCP homologues lacking a resolving cysteine have been assumed to function via the 1-Cys 
Prx pathway. However, the mechanistic details of such enzymes have never been fully 
characterized. In light of the novel pathway adopted by the engineered EcBCP C50S enzyme 
(3), we sought to define the catalytic mechanism employed by native BCP homologues that 
lack a resolving cysteine. We herein characterize one such member of the BCP family; the 
BCP Prx of Burkholderia cenocepacia, an aerobic Gram-negative organism that belongs to a 
group of closely-related bacterial species referred to as the B. cepacia complex (Bcc) (4). B. 
cenocepacia is a significant pathogen of the cystic fibrosis (CF) lung, an environment that is 
considered highly oxidative as a consequence of the profound influx of neutrophils and the 
resulting release of ROS. In addition, B. cenocepacia is capable of surviving the oxidative 
burst within activated macrophages (5, 6). Consequently, anti-oxidant activities are thought to 
play a role in the ability of this organism to establish chronic infection of the CF airways.  
We previously reported that the bcp homologue of B. cenocepacia is coexpressed with the arn 
locus (7). The arn locus encodes the biosynthetic enzymes required for the modification of 
lipopolysaccharide with aminoarabinose, a positively-charged sugar that lowers the binding 
affinity of cationic antimicrobial peptides, thus conferring resistance (8). Such antimicrobial 
peptides are the dominant mechanism of non-oxidative killing by phagocytic cells. Thus, the 
genetic linkage of bcp with the arn locus within Burkholderia species combines putative 
resistance mechanisms against both oxidative and non-oxidative killing by phagocytes. In the 
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present study, we demonstrate that the BCP of B. cenocepacia displays the anticipated thiol-
dependent peroxidase activity, which protects against oxidative stress in a growth-phase 
dependent manner. The native enzyme, which lacks a resolving cysteine, functions via a 1-
Cys catalytic pathway, whilst introduction of a resolving cysteine switches the catalytic 
pathway to an atypical 2-Cys mechanism that is functionally indistinguishable from that of 
the E. coli enzyme. We conclude that the BCP family of bacterial Prxs can be subdivided on 
the basis of catalytic activity, and that the 1-Cys peroxidatic mechanism, typified by the 
Burkholderia enzyme, represents the dominant class. 
EXPERIMENTAL PROCEDURES 
Bacterial strains, macrophages and culture conditions. B. cenocepacia strain K56-2 was used 
in this study. Based on multilocus sequence typing (MLST), B. cenocepacia K56-2 belongs to 
the same clonal complex as the genome sequence strain B. cenocepacia J2315, a 
representative of the highly transmissible ET12 epidemic lineage. B. cenocepacia XOA14 
was created by insertional inactivation of the B. cenocepacia K56-2 bcp homologue 
(corresponding to BCAL1936 of B. cenocepacia J2315) using the pGPΩTp suicide plasmid 
(9). E. coli strains DH5α and BL21(DE3) were used for cloning and protein expression 
respectively. All bacterial strains were routinely grown at 37 °C in Luria Bertani (LB) 
medium. Burkholderia cultures were supplemented as required with 100 μg/ml of 
trimethoprim (Tp), 100 μg/ml tetracycline (Tet) and/or 50 μg/ml of gentamicin (Gm). E. coli 
cultures were supplemented with Tp (50 μg/ml), Tet (20 μg/ml) or kanamycin (30 μg/ml). 
Bacterial strains are listed in Table 1. 
The murine macrophage cell line RAW264.7 was obtained from the American Type Culture 
Collection. ANA1 macrophages were a gift of Danuta Radzioch, McGill University, Quebec, 
 7 
Canada. Cells were maintained in DMEM with 10% fetal bovine serum and grown at 37°C 
with 5% carbon dioxide. 
Cloning and site-directed mutagenesis of BCP.  The bcp gene of B. cenocepacia K56-2 was 
PCR amplified (PfuUltra II Fusion HS DNA Polymerase, Stratagene), incorporating NdeI and 
BamHI restriction sites into the forward and reverse primers respectively, enabling ligation 
into NdeI/BamHI-digested pET-28a vector (Novagen). This resulting vector, pARB1, encodes 
wildtype (WT) BcBCP with an N-terminal 6-His tag. His-tagged WT EcBCP was expressed 
from a comparable vector (pARB5) following amplification of the open-reading frame from 
E. coli K12. Using pARB1 vector as template and the QuikChange II Site-Directed 
Mutagenesis Kit (Stratagene), three mutant open-reading frames of BcBCP were created: 
C44S (pARB2), C98S (pARB3) and L49C (pARB4). The resulting plasmids (pARB1 – 
pARB5) were used to transform E. coli strain BL21 (DE3). Primer sequences used for cloning 
and site-directed mutagenesis are available upon request. 
Expression and purification of BCP enzymes. E. coli BL21 (DE3) cells transformed with the 
appropriate BCP-encoding plasmid were cultured overnight at 37 °C in 50 ml LB medium 
supplemented with kanamycin (30 μg/ml). Overnight cultures were used to inoculate 1 litre of 
fresh medium, which was cultured to an optical density at 600 nm of approximately 0.6. 
Isopropyl-1-thio-β-D-galactopyranoside (IPTG) was added to a final concentration of 0.25 
mM and cultures incubated for 3 h. Cells were harvested by centrifugation and resuspended in 
20 ml Tris (50 mM), NaCl (500 mM), imidazole (20 mM), pH 7.5. Cells were disrupted by 
sonication and lysates centrifuged. Clarified supernatant was filtered (0.45 µM) prior to 
loading onto a HisTrap FF 5 ml column (GE Healthcare). His-tagged BCP protein was eluted 
from the nickel column with increasing imidazole concentration and de-salted using a PD 
Miditrap G-25 column (GE Healthcare), eluting in Hepes-NaOH (pH 7.0).  
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Determination of thioredoxin-linked peroxidase activity of BCP. Thioredoxin-linked 
peroxidase activity was assessed essentially as described previously (2). In brief, reactions 
were performed at room temperature in 500 µL volumes, comprising 0.36 µM thioredoxin 
reductase (TrxR; Sigma-Aldrich), 1.7 µM thioredoxin (Trx; Sigma Aldrich), 0.1 mM 
hydrogen peroxide and 0.2 mM NADPH (Roche) in 50 mM Hepes-NaOH (pH 7). BCP 
concentrations were variable, ranging from 0 to 16 μM. Peroxide was added to the reaction 
mixture last, and the absorbance at 340 nm was measured continuously for 5 min. The assay 
was also performed with 1 mM GSH in the reaction mixture. 
Determination of glutaredoxin-linked peroxidase activity of BCP. Reactions were performed 
at room temperature in 500 µL volumes, comprising 1 unit glutathione reductase 
(Calbiochem), 12 µM glutaredoxin (Grx, Calbiochem), 1 mM reduced glutathione (GSH, 
Sigma-Aldrich), 0.1 mM hydrogen peroxide and 0.15 mM NADPH (Roche) in 50 mM Hepes-
NaOH (pH 7). BCP concentrations were variable, ranging from 0 to 16 μM. Peroxide was 
added to the reaction mixture last, and the absorbance at 340 nm was measured continuously 
for 5 min. 
H2O2 oxidation. Typically, wildtype and mutant BCP proteins were at a concentration of 50 
µM in ammonium acetate (100 mM, pH 7.2), GSH was added to a final concentration of 
1mM before reaction with H2O2. Typically, oxidation was allowed to proceed for a few 
seconds before the addition of 4-fold H2O:MeOH:HCOOH (50:48:2) (v/v) quenched the 
reaction. 
Preparation of reduced thioredoxin and glutaredoxin. Thioredoxin and glutaredoxin were 
resuspended in 100 mM ammonium acetate (pH 7.2) before reduction with 2 mM TCEP. 
Excess TCEP was removed by buffer exchange using a PD-Miditrap desalting column (GE 
Healthcare) and the sample was eluted in 50 mM ammonium acetate, pH 5.5.  Disulfide bond 
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reduction was verified by FT-ICR-MS and the reduced protein was stored at 4 °C. Protein 
concentration was measured using the BCA assay (Pierce, Rockford, IL). 
Reaction of oxidized BCP species with reduced thioredoxin or glutaredoxin. Oxidized wild-
type and L49C BCP species were produced by treatment of 50 µM protein with 100 µM 
hydrogen peroxide, in the presence of 1 mM GSH. The resulting oxidized species were 
purified by PD-Miditrap desalting column (GE Healthcare) and eluted with 200mM 
ammonium acetate (pH 7.2).  The samples (10 µM) were then treated with 10 µM reduced 
thioredoxin or glutaredoxin and incubated at room temperature for 5 min. The reaction was 
quenched with 2-fold H2O:MeOH:HCOOH (v/v/v 50:48:2), and analyzed by FT-ICR-MS.  
FT-ICR mass spectrometry. Protein samples were buffer exchanged into 100 mM ammonium 
acetate, pH 7.4 before addition of hydrogen peroxide and mass spectrometry analysis. 
Reactions were quenched with 2-fold H2O:MeOH:HCOOH (v/v/v 50:48:2), and analyzed by 
FT-ICR-MS. Mass spectrometry data was acquired on an Apex Ultra Qh-FT-ICR mass 
spectrometer equipped with a 12 Tesla superconducting magnet and an electrospray ion 
source (Bruker Daltonics, Billerica, MA). Nano-ESI was performed using a TriVersa 
Nanomate (Advion BioSciences, Ithaca, NY) running in infusion mode. Broadband data was 
typically acquired between m/z 600 and 4000 for 0.5 s and each spectrum was the sum of 32 
scans. The mass spectra were externally calibrated using ES tuning mix (Agilent) and 
analyzed using DataAnalysis software (Bruker Daltonics).  Isotope distributions of specific 
charge states were predicted using IsotopePattern software (Bruker Daltonics) from 
theoretical empirical formulae. These were overlaid upon the recorded experimental data as 
scatter plots, with the theoretical apex of each isotope peak designated by a circle.   
Top-Down FT-ICR-tandem mass spectrometry. Top-down fragmentation was performed on 
the 12T Qh-FT-ICR. First, a specific ion species was isolated with the instrument’s mass 
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resolving quadrupole and MS/MS was performed using collision-induced dissociation (CID) 
or electron capture dissociation (ECD). For CID, the collision voltage was typically set 
between 20-35V.  For ECD, 1.8 amperes was applied to the dispenser cathode filament 
(Heatwave Technologies), 20V to the lens and a pulse of 4-9 ms was employed. 
Fragmentation data was the sum of 250-750 scans and data analyses were performed using 
DataAnalysis (Bruker Daltonics). The SNAP algorithm was used for automated peak picking 
and the resulting top-down fragment mass lists were searched against the primary sequence of 
BCP using Prosight-PTM software (10, 11). Mass error tolerances were set for all Prosight 
searches at 10 ppm.  
Complementation of BCP function. The N-terminal 6-His tagged WT bcp ORF was PCR 
amplified from pARB1, incorporating EcoRI and XbaI restriction sites into the forward and 
reverse primers respectively. The ORF was subsequently ligated into EcoRI- and XbaI-
digested pDA17 vector (TetR), generating pARB10. pARB10 was introduced into XOA14 by 
triparental mating, resulting in strain ARB201.  Expression of 6-His-tagged BcBCP was 
confirmed by Western analysis of whole-cell lysates using anti-His antibody (GE Healthcare) 
and HRP-linked anti-mouse IgG (Cell Signaling Technology). 
Expression analysis of BCP. B. cenocepacia K56-2 was grown to logarithmic phase in LB 
prior to isolation of RNA (RNeasy Protect Bacteria Mini, Qiagen), DNAse treatment (RNase-
free DNase set, Qiagen) and subsequent cDNA synthesis (SuperScript III Reverse 
Transcriptase, Invitrogen). To assess expression of bcp and representative genes from the 
upstream arn locus (arnT and arnB), quantitative real-time PCR (QRT-PCR) was performed 
using the Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen) in a 25 µL reaction 
volume containing 10 μL of 1 in 100 diluted cDNA, 400 nM primers and 4 % (v/v) DMSO. 
All primer pairs exhibited PCR efficiencies between 90 and 104 %, with R2 values greater 
than 0.99 over at least a 103 range of template concentrations. Primer sequences are available 
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upon request. Thermal cycling was performed on a Stratagene Mx3000P thermal cycler and 
data analyzed using the Comparative Quantitation algorithm. Dissociation curve analysis and 
electrophoresis of representative samples confirmed identity of PCR products. 
Northern blot analysis was performed according to standard procedures, with 32P-labelled 
probes prepared using the RadPrime DNA Labeling System (Invitrogen). 
Assessment of sensitivity to hydrogen peroxide. Strains were grown in LB without 
supplements. At appropriate time points throughout the growth phase, culture aliquots were 
removed to fresh culture vessels and challenged with either hydrogen peroxide (to a final 
concentration of 1 mM) or an equivalent volume of PBS (control). After 30 min incubation at 
37 °C, appropriate serial dilutions were plated, allowing viable counts and percentage survival 
to be determined. 
Macrophage infection assays.  Macrophage infection assays were performed to assess 
intracellular survival of B. cenocepacia. To quantify intracellular survival, bacteria were 
added to macrophages at a multiplicity of infection (MOI) of 50 bacteria per macrophage, and 
internalization of bacteria was allowed to proceed for 2 h. Following internalization, cell 
culture medium was supplemented with ceftazidime (1 mg/ml) and kanamycin (500 μg/ml) to 
kill remaining extracellular bacteria. The number of surviving intracellular bacteria at 2 and 4 
h post-internalization was determined by triplicate plating of serially diluted macrophage cell 
lysate.  
Localization of Burkholderia within macrophages was assessed using tetramethyl-rhodamine-
dextran (TMR-dextran) to label lysosomes, and LysoTracker Red to label acidic 
compartments. For lysosome labeling prior to bacterial infection, ANA-1 macrophages were 
incubated with 250 µg/mL TMR-dextran (Molecular Probes) for 2 h, followed by a 1 h chase 
in dye-free medium to ensure full delivery of TMR-dextran to lysosomes. Macrophages were 
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infected at MOI 50 and incubated for a further 2 or 4 h, prior to visualization using 
differential interference contrast (DIC) and fluorescence microscopy to quantify the 
percentage of Burkholderia cepacia-containing vacuoles (BcCVs) colocalizing with TMR-
dextran.   
For labeling of acidic compartments with LysoTracker Red, RAW264.7 macrophages were 
infected with bacteria at an MOI of 50. At 4 h postinfection (and immediately prior to 
visualization by DIC and fluorescence microscopy), acidic compartments within infected 
macrophages were labeled by incubation with LysoTracker Red DND-99 (Molecular Probes) 
at a final concentration of 0.25 µM for 1 min. 
RESULTS 
Burkholderia BCP displays thiol-dependent peroxidase activity. Based on homology with 
known BCP peroxiredoxins, it was predicted that BcBCP would exhibit thiol-dependent 
peroxidase activity. N-terminal 6His-tagged recombinant WT BcBCP was expressed and 
purified to homogeneity using a nickel affinity column. Gel filtration of the protein showed it 
to behave as a monomer with a mass of approximately 19 kDa, which was subsequently 
confirmed by ESI mass spectrometry (average mass 18992 Da). 
The peroxidase activity of BcBCP linked to oxidation of NADPH via the E. coli 
thioredoxin/thioredoxin reductase (Trx/TrxR) system was monitored spectrophotometrically 
by measuring the decrease in A340. In the absence of BcBCP, a background level of NADPH 
oxidation occurred at a steady rate of 0.10 µMmin-1. In the presence of BcBCP, the rate of 
NADPH oxidation increased in a BCP concentration-dependent manner and was recorded as 
1.04 ± 0.08 0.1 µMmin-1 per µM of BCP (µMmin-1µM-1). Comparable BCP enzyme activity 
was observed in the presence of all peroxide substrates tested (hydrogen peroxide, cumene 
hydroperoxide and tert-butyl hydroperoxide). Pre-treatment of BcBCP with iodoacetamide 
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(IAM; 10 mM final concentration), which covalently modifies free thiol groups, abolished 
enzyme activity (0.10 µMmin-1µM-1), confirming that the activity of BcBCP is thiol-
dependent.  
Cys-44 is the active site of Burkholderia BCP. Site-directed mutants of BcBCP were 
generated, in which each of the cysteine residues was individually replaced with a serine 
(C44S and C98S BcBCP). The enzymatic activity of these mutants was studied as before. 
Activity was abolished in the C44S mutant (Figure 1). In contrast, C98S BcBCP retained full 
enzyme activity. Together, these findings are consistent with the Cys-44 residue being the 
active site of the thiol-dependent BcBCP, whilst the Cys-98 residue is a bystander, not 
involved in the catalytic process. This is consistent with previous observations made of the 
equivalent cysteine residues (Cys-45 and Cys-99) of EcBCP (2).  
The Cys-44 residue of BcBCP was confirmed as the active (peroxidatic) cysteine by mass 
spectrometry (Figure 2). Treatment of WT BcBCP with 10 molar equivalents of H2O2 resulted 
in an increased mass of 32 Da, consistent with one free thiol group (-SH) being oxidized to 
the sulfinic acid derivative (-SOOH, Figure 2B). Following treatment with H2O2, the mass of 
C98S BcBCP similarly increased whilst the mass of C44S BcBCP remained unchanged, 
suggesting that it is the Cys-44 residue that is oxidized during the catalytic process (data not 
shown). Top-down fragmentation of the oxidized wildtype enzyme, using ECD, subsequently 
mapped the sulfinic acid modification to Cys-44, confirming that residue as the peroxidatic 
cysteine (Figure 2C and Supporting Information Figure S1). 
Burkholderia BCP is a 1-Cys peroxiredoxin. E. coli BCP functions via an atypical 2-Cys 
pathway, employing a peroxidatic cysteine at position 45 and a resolving cysteine at position 
50 (3). However, BcBCP lacks the equivalent resolving cysteine (Figure 3). We previously 
demonstrated that in the absence of the resolving cysteine, EcBCP (C50S) adopts a novel 
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mechanistic pathway, progressing via a dimeric intermediate, which contains an 
intermolecular disulfide bridge between the Cys-45 residues of two monomers (3). The native 
BcBCP was interrogated by high-resolution mass spectrometry to investigate if it too adopts 
this novel reaction pathway.  
As stated above, in excess H2O2 and in the absence of any redox partner, BcBCP forms a 
stable sulfinic acid (Cys-SOOH), suggesting overoxidation of a sulfenic acid intermediate. 
However, even at stoichiometric quantities of H2O2, no evidence for dimerization was 
observed by mass spectrometry. This result led us to speculate whether BcBCP could utilize a 
small molecule thiol as a resolving partner in a manner previously described for 1-Cys 
peroxiredoxins (12-16). 
A mechanistic study of the 1-Cys D-Prx has highlighted the interaction of glutathione (GSH) 
with the enzyme during turnover (14). Therefore, experiments with BcBCP were repeated in 
the presence of 1mM GSH. Mass spectrometry shows that in the presence of GSH, but 
absence of H2O2, BcBCP exists as a monomer with two reduced cysteine thiols (Figure 4A). 
After addition of 1 molar equivalent of H2O2, we observed the appearance of a species with 
∆mass +305 Da, consistent with the formation of a BcBCP-GSH heterodimer (Figure 4B). 
Presumably, GSH modification is via a mixed disulfide bond with one of the two cysteine 
residues within BCP. To map the site of glutathionylation, top-down fragmentation was 
employed. The BcBCP-GSH heterodimer was treated with the alkylating reagent N-ethyl 
maleimide (NEM) to covalently modify any free cysteine thiols. This resulted in an increase 
of +125 Da, consistent with the alkylation of one cysteine residue. The NEM-labeled GSH-
modified species was then reduced by treatment with 20 mM DTT, resulting in a ∆mass of -
305 Da, which we attribute to loss of GSH. This mass change confirmed that the 
glutathionylation modification was indeed via a disulfide bond.  This final species was subject 
to CID fragmentation using FT-ICR MS. Analysis of the resulting fragments allowed the 
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NEM modification to be mapped to Cys-98, indicating that the glutathionylation occurred on 
the active cysteine, Cys-44 (Figure 4C and Supporting Information  Figure S2).  
Glutaredoxin can act as the reductive partner to BcBCP in a glutathione-dependent catalytic 
pathway. These mass spectrometric results suggest that GSH acts as a small molecule 
resolving cysteine, reducing the transient sulfenic acid intermediate on Cys-44 releasing H2O 
and producing a mixed disulfide between Cys-44 and GSH. If this hypothesis is correct, the 
resulting BcBCP-GSH intermediate requires a reductive partner. This partner must reduce the 
intermolecular disulfide bond, regenerating a reduced peroxidatic cysteine on BcBCP, which 
would allow further catalytic cycles. Using high-resolution mass spectrometry, we monitored 
the ability of thioredoxin to reduce the BcBCP-GSH intermediate. BcBCP-GSH was prepared 
by treating reduced BcBCP with 2 equivalents of H2O2 in the presence of 1mM GSH (as 
shown in Figure 4B). Excess GSH and peroxide were removed using size exclusion 
chromatography before this species was incubated with an equimolar ratio of reduced 
thioredoxin. The mixture was equilibrated at room temperature for 2 min before analysis by 
FT-ICR MS (Supporting Information Figure S3). Analysis of the isotopic distributions within 
the resulting mass spectrum revealed no mass shift for either species, suggesting that 
thioredoxin is not an efficient reducing partner for BcBCP-GSH. This observation seemed to 
contradict results from the Trx/TrxR enzyme assay that demonstrated enzyme turnover using 
thioredoxin as the reducing partner. However, repeating the enzyme assay in the presence of 
1mM GSH resulted in a dramatic loss of enzyme activity, recorded at 0.19 ± 0.05 µMmin-
1µM-1  (Figure 1). This result suggests that glutathionylation of the peroxidatic cysteine 
inhibits the thioredoxin-dependent reductive step of catalysis. Together, these observations 
imply that thioredoxin can act as a reductant in BcBCP catalysis by directly reducing the 
transient Cys44-S-OH intermediate to Cys44-SH. However, in the presence of GSH, the 
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transient Cys44-S-OH is quickly glutathionylated. The resulting BcBCP-GSH mixed disulfide 
is not a substrate for reduction by thioredoxin and BcBCP turnover is inhibited.  
As stated above, glutathione-dependent catalysis has been reported previously for 
peroxiredoxin enzymes - the poplar phloem 1-Cys D-Prx has been extensively studied and 
displays glutathione dependence (15, 16). Furthermore, NMR and MS studies of this enzyme 
have revealed that the poplar Prx can be glutathionylated on its peroxidatic cysteine residue 
and the enzyme accepts glutaredoxin (Grx) as a proton donor (14). Using high resolution MS, 
we monitored the ability of glutaredoxin to reduce the BcBCP-GSH intermediate. Equimolar 
ratios of reduced Grx and BcBCP-GSH were mixed and equilibrated at room temperature for 
2 min. After allowing the reaction to proceed, FT-ICR MS analysis revealed that Grx 
displayed a ∆mass of -2Da, consistent with oxidation of Grx and formation of an 
intramolecular disulfide bond; and the BcBCP species underwent a mass shift of -305 Da, 
consistent with reduction of the glutathione moiety, and displayed an isotope distribution 
consistent with BcBCP containing two reduced cysteines (Figure 5). This result indicates that 
Grx can efficiently reduce the BcBCP-GSH mixed disulfide. 
In light of these mass spectrometric results, BcBCP was assayed for peroxiredoxin activity 
using an NADPH-linked GSH/Grx/glutathione reductase system, and was monitored 
spectrophotometrically by measuring the decrease in A340. As expected, NADPH oxidation 
was observed in the presence of BCP and activity increased in a BCP concentration-
dependent manner (Figure 6). BcBCP displayed an activity of  6.10 ± 0.04 µMmin-1µM-1 and 
was dependent on the presence of Grx and GSH in the reaction. Interestingly, this activity is 
greater than 5-fold higher than the activity using Trx/TrxR as a reducing system under similar 
conditions.  
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Introduction of Cys49 converts Burkholderia BCP to an atypical 2-Cys Prx. To investigate 
the differences between the E. coli and Burkholderia BCP homologues, a resolving cysteine 
was introduced into BcBCP (L49C) at an equivalent position to the resolving cysteine of the 
E. coli enzyme (Cys-50).  
The activity and catalytic mechanism of L49C BcBCP was examined by mass spectrometry. 
Oxidation of L49C BcBCP with H2O2 resulted in a ∆mass of -2 Da, which we attribute to the 
loss of two hydrogen atoms, consistent with the formation of an intramolecular disulfide bond 
between two cysteines (Figure 7A and 7B). This disulfide bond was formed upon treatment 
with peroxide both with and without the presence of 1 mM GSH. Disulfide bond formation 
was confirmed by treatment of the oxidized protein with NEM, which resulted in the 
modification of only a single thiol group (data not shown). The site of NEM-modification was 
examined by top-down fragmentation. CID fragmentation revealed that Cys-98 was modified 
by NEM, and that Cys-44 and Cys-49 formed the intramolecular disulfide bond (Figure 7C 
and Supporting Information Figure S4). Together, these results demonstrate that the L49C 
BcBCP mutant acts via the atypical 2-Cys Prx mechanism, in a manner similar to EcBCP.  
Having demonstrated by MS that L49C BcBCP functions as an atypical 2-Cys Prx, we 
investigated the activity of the enzyme using the previously described enzyme assays. 
Although less active than the wildtype enzyme, L49C BcBCP displays an activity of  0.59 ± 
0.06 µMmin-1µM-1 using Trx/TrxR as the reductive partners (Figure 1), confirming that the 
Cys44-Cys49 intramolecular disulfide bond can be resolved by the Trx/TrxR redox system. 
This activity was not inhibited by the presence of GSH. L49C BCP was also compared to the 
native E. coli enzyme, as the catalytic mechanism of these enzymes appears identical by MS. 
The activity of the native E. coli enzyme was 4-fold greater than that of L49C BcBCP (Figure 
1). Indeed, EcBCP displayed greater activity than all isoforms of BcBCP (WT and site-
directed mutants) using this assay with Trx/TrxR as the reductive partners (Figure 1).  
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Analyzing the activity of the BcBCP L49C using the GSH/Grx system, we found that 
introduction of the cysteine resulted in an activity of 0.47 ± 0.09 µMmin-1µM-1, a 15-fold 
decrease in comparison to wild-type BcBCP (Figure 6). We also assayed the activity of WT 
EcBCP using this assay. Again, this enzyme showed significantly lower activity than WT 
BcBCP (Figure 6). These results suggest that the GSH/Grx system is not an efficient reducing 
partner for peroxiredoxins that catalyze peroxide reduction via the 2-Cys mechanism. 
Presumably this system cannot reduce the intramolecular disulfide formed in the reaction 
pathway of these enzymes. To test this hypothesis, the redox exchange reaction between 
oxidized BcBCP L49C and reduced glutaredoxin/GSH was monitored by MS. An equimolar 
mixture of oxidized BcBCP L49C and reduced glutaredoxin was allowed to equilibrate for 2 
min in the presence of 1 mM GSH, before analysis by FT ICR-MS. As expected, analysis of 
the isotopic abundances within the resulting mass spectrum revealed that both species were 
unchanged (Supporting Information Figure S5, top) - highlighting the inability of Grx/GSH to 
reduce the Cys44-Cys49 disulfide bond within BcBCP L49C. In a similar experiment, no 
reduction of oxidized wild-type EcBCP by Grx/GSH was observed by FT-ICR MS (data not 
shown).  In contrast, MS analysis of the redox exchange reaction between BcBCP L49C and 
reduced thioredoxin, demonstrates that thioredoxin can reduce oxidized BcBCP L49C. 
However, it is interesting to note that to fully reduce BcBCP L49C, thioredoxin was added in 
5-fold molar excess (Supporting Information Figure S5, bottom). These MS results correlate 
with the enzyme assay results (presented here and in ref. 3) which suggest that Trx is the 
preferred redox partner for the 2-Cys Prxs EcBCP and BcBCP L49C.   
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The Burkholderia bcp gene shows unique linkage and coexpression with the arn locus. We 
previously reported that the gene encoding BcBCP (BCAL1936; B. cenocepacia J2315 gene 
nomenclature) is coexpressed with the arn locus (BCAL1929-1935) (7). Here, we further 
investigated this intriguing linkage of two different, but complementary, resistance 
determinants through comparative genomic analyses and quantitative gene expression studies.  
Analysis of publicly available genomes that contain a bcp homologue revealed that the 
linkage of bcp with the arn locus is unique to β-proteobacteria that exhibit innate resistance to 
the polymyxin class of antimicrobials (Burkholderia species and the closely-related Ralstonia 
pickettii lineage). The genetic organization of the locus is shown in Figure 8. In the majority 
of polymyxin-sensitive β-proteobacteria studied, including Bordetella, Comamonas and 
Delftia species, the bcp gene is flanked by homologues of BCAL1928 and BCAL1937 
without the intervening arn locus. In contrast, in γ-proteobacteria (including Salmonella, 
Shigella and Pseudomonas species), there is conserved linkage of the bcp and gcvR genes, the 
latter coding for the glycine cleavage repressor protein (17). This is consistent with the 
previous report that the E. coli bcp gene is located immediately downstream of the gcvR gene, 
but expressed independently (18). It should be noted that β-proteobacteria generally do not 
possess orthologs of GcvR (19). 
Northern blot analysis of B. cenocepacia K56-2 at logarithmic phase revealed the presence of 
an abundant bcp transcript of approximately 830 bp, suggesting that bcp is strongly expressed 
independently, in addition to its previously described coexpression with the arn locus (7). We 
previously reported that the Burkholderia arn locus is expressed as two transcriptional units. 
Consequently, the independent expression of bcp was investigated further by QRT-PCR, 
comparing the level of bcp expression with that of representative genes from each 
transcriptional unit of the arn locus (arnT and arnB). The abundance of bcp transcript was 
approximately 11-fold higher than both arnT and arnB (Supporting Information Figure S6), 
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confirming the strong independent expression of bcp. A comparable ratio of transcripts was 
observed irrespective of the growth phase studied (data not shown). 
Burkholderia BCP confers growth-phase-dependent resistance to oxidative killing. Insertional 
inactivation of the bcp gene in B. cenocepacia K56-2 resulted in strain XOA14. To explore 
the role of BcBCP, the sensitivity of K56-2 and XOA14 to oxidative killing was assessed at 
regular timepoints throughout the growth phase. As shown in Figure 9, XOA14 is 
hypersensitive to H2O2-mediated killing, however this hypersensitivity is restricted to the lag 
phase / early log phase of growth. At stationary phase, there is no difference in the survival of 
XOA14 and K56-2 following treatment with H2O2. The hypersensitivity of XOA14 to 
oxidative killing at lag phase could be rescued through complementation with WT BcBCP 
encoded on plasmid pARB10 (Supporting Information Figure S7). 
Burkholderia BCP is not required for intracellular survival. Having demonstrated 
hypersensitivity to oxidative killing, the ability of XOA14 to survive within macrophages was 
assessed, and compared with K56-2. Cumulative evidence suggests that Bcc do not actively 
replicate intracellularly (20, 21). Consequently, we consider the use of stationary phase 
bacteria to be most physiologically relevant for Bcc intracellular survival assays. However, 
given the growth phase-dependent hypersensitivity of XOA14 to peroxide-mediated killing, 
we investigated intracellular survival and/or intracellular localization using both early log 
phase and stationary phase bacteria.  
As shown in Figure 10A, intracellular survival of early log phase XOA14 is no different from 
that of K56-2, suggesting that the role of BcBCP is to protect from oxidative stresses in the 
extracellular rather than intracellular environment. Stationary phase bacteria were then used to 
compare the localization of K56-2 and XOA14 within macrophages (Figure 10B). The 
persistence of Bcc within macrophages in the apparent absence of replication has been 
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associated with their ability to delay the maturation of the phagosome, persisting instead 
within B. cepacia-containing vacuoles (BcCVs) (for review, see 22). Key events in the 
maturation of phagosomes include their progressive acidification and ultimately fusion with 
lysosomes. These processes can be monitored using LysoTracker Red and TMR-dextran, 
which (when visualized by fluorescence microscopy) label acidic organelles and lysosomes 
respectively. Microscopy of infected macrophages allows BcCVs to be visualized, and the 
percentage of BcCVs colocalizing with either LysoTracker Red or TMR-dextran can be 
calculated. A strain that is impaired in its ability to persist intracellularly (by delaying 
phagosomal maturation) would be expected to yield a higher proportion of LysoTracker Red 
and/or TMR-dextran-colocalizing BcCVs. The BCP-deficient XOA14 displays a marginally 
higher proportion of LysoTracker Red- and TMR-dextran-colocalizing BcCVs 4 h post 
infection compared to K56-2, but these differences are not statistically significant (Figure 
10B). Therefore, we conclude that BcBCP is not critical for the intracellular survival of B. 
cenocepacia in murine macrophages.  
DISCUSSION 
BCP is a thiol-dependent Prx of the AhpC/TSA family that is present in diverse bacterial 
species. Recently, we re-classified EcBCP, the founder member of this group of enzymes, as 
an atypical 2-Cys Prx on the basis of high resolution MS analysis (3). In the present study, we 
describe the BCP of B. cenocepacia, a novel member of the BCP family and an addition to 
the repertoire of ‘superoxide detoxification’ gene products recently identified within the B. 
cenocepacia J2315 genome (23). We provide the first detailed characterization of the 1-Cys 
BCP-peroxidatic mechanism, and demonstrate that BCP homologues fall into one of two 
functional groups, based on the presence or absence of a resolving cysteine (Figure 11). In the 
presence of the resolving cysteine, as typified by EcBCP, the sulfenic acid intermediate that 
forms following oxidation of the peroxidatic cysteine is rapidly reduced through the formation 
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of an intramolecular disulfide bond with the resolving cysteine (atypical 2-Cys Prx 
mechanism). Crucially, this occurs even in the presence of excess GSH (3), indicating that in 
the presence of the resolving cysteine, the formation of the intramolecular disulfide bond is 
strongly favored over the formation of a BCP-GSH heterodimer. This intramolecular disulfide 
bond is subsequently reduced by thioredoxin, completing the catalytic cycle. In contrast, 
BcBCP described in the present study, lacks the resolving cysteine. This enzyme displays 
moderate enzymatic activity using thioredoxin, presumably with Trx directly reducing the 
sulfenic acid intermediate. However, here we demonstrate that in the presence of GSH this 
Trx-dependent catalysis is inhibited. Furthermore, the enzyme forms a rapid BCP-GSH 
heterodimer following oxidation of the peroxidatic cysteine, in a manner previously described 
by Noguera-Mazon et al. (14). We show that this resolving complex is not a substrate for 
reduction by thioredoxin, but by the redox partner glutaredoxin. Introduction of a resolving 
cysteine (L49C) converts the Burkholderia enzyme to an atypical 2-Cys Prx that can be 
reduced by thioredoxin, thus retaining enzyme activity. A schematic of the WT and L49C 
BcBCP reaction mechanisms is shown in Figure 11.  
BCP homologues found in the majority of bacterial species lack the equivalent of the EcBCP 
resolving cysteine (Cys-50) (Supporting Information Figure S8 and ref. 3). Of 59 BCP 
proteins represented in Figure S8, only 18 have a cysteine residue at the equivalent position of 
the E. coli Cys-50, and these 18 BCP homologues are almost exclusively found in a restricted 
set of gamma proteobacteria. The majority of bacterial BCP homologues, from taxonomically 
diverse bacterial species, lack an apparent resolving cysteine and are presumed to exhibit the 
1-Cys mechanism, typified by the native Burkholderia enzyme.  
We previously reported that the engineered C50S EcBCP retains activity through a novel 
catalytic mechanism that is distinct from the 1-Cys pathway (3). In contrast, we have 
demonstrated in the current study that the native BcBCP that lacks the equivalent resolving 
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cysteine functions via a GSH/Grx dependent 1-Cys pathway. Interesting, we also assessed the 
activity of the EcBCP C50S mutant in the Grx assay (Figure 6). This single-cysteine BCP 
mutant displays activity approaching the level of BcBCP in this assay, suggesting it can also 
act via a BCP-GSH mixed disulfide resolving complex. In our previous study, MS analysis of 
the EcBCP C50S was performed without the presence of GSH. MS analysis of this enzyme 
after oxidation with peroxide was repeated in the presence of 1 mM GSH and reveal a mixture 
of both BCP-GSH and BCP-BCP mixed disulfide dimers (data not shown). Thus, it seems 
that two resolving-pathways can be used by this BCP-variant. In contrast, no evidence for 
intermolecular disulfide bond formation and BCP dimers was found for WT BcBCP. 
Comparison of the amino acid sequences of representative BCP homologues shows that in 
atypical 2-Cys enzymes that possess an equivalent resolving cysteine to EcBCP (Cys-50), the 
conserved region that encompasses the peroxidatic cysteine extends up to (and beyond) the 
resolving cysteine (Supporting Information Figure S9). In contrast, BCP homologues that lack 
the resolving cysteine are divergent after the active TPGCT motif. It may be that these 
differences in amino acid sequence and thus architecture around the peroxidatic cysteine 
account for the subtle differences observed between the engineered C50S EcBCP enzyme and 
the native Burkholderia enzyme. There may be merit in high-resolution 3D structural studies 
of these BCPs to further explore the link between these isoform-specific sequence differences 
and catalytic mechanism. Such studies of the BCP homologue of Xanthomonas campestris 
(XcBCP) have recently been reported (24). Whilst XcBCP possesses a resolving cysteine and 
functions as an atypical 2-Cys Prx, it differs from EcBCP in the positioning of the resolving 
cysteine relative to the peroxidatic cysteine. The peroxidatic and resolving cysteines of 
EcBCP (Cys-45 and Cys-50, respectively) are present within the same α-helix, but the 
equivalent cysteines of XcBCP (Cys-48 and Cys-84, respectively) are in different α-helices 
(24). Consequently, the proposed pathway of alternate opening and closing of the substrate 
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entry channel and disulfide bond pocket in XcBCP (24) is unlikely to be directly applicable to 
the E. coli enzyme or, indeed, the 1-Cys BcBCP. Equivalent studies of the EcBCP and BcBCP 
homologues are required to establish the structural changes that occur in the catalytic cycles 
of these 1-Cys and 2-Cys BCP variants. 
The BCP-associated phenotype shows variation between different bacterial species. Whilst 
BCP-deficient B. cenocepacia and E. coli (2) are hypersensitive to hydrogen peroxide, BCP-
deficient Helicobacter pylori are not (25). This variable phenotype is most likely a 
consequence of differences in the repertoire and relative abundance of other anti-oxidant 
proteins within the cell. In the case of H. pylori, the 2-Cys AhpC peroxidase is considerably 
more abundant than BCP. Consequently, an ahpC-deficient H. pylori mutant is significantly 
more sensitive to oxidative killing than the bcp-deficient mutant (25). Indeed, given that we 
observed consistent expression (at the transcript level) of bcp throughout the growth phase of 
B. cenocepacia, we believe that the growth phase-dependent phenotype of the BCP-deficient 
strain XOA14 is a consequence of other anti-oxidant factors being strongly induced at late 
exponential / stationary phase, thus rendering BcBCP essentially redundant. Several anti-
oxidants identified within the Bcc as playing a decisive role in intracellular survival show 
dramatically increased activities at stationary phase, including superoxide dismutase (SodC), 
catalase enzymes (including the bifunctional catalase-peroxidase, KatB) and a melanin-like 
pigment (26-29). Similarly, an apparent AhpC-deficient variant of B. cenocepacia C1394 is 
hypersensitive to oxidative killing at stationary phase relative to the parent strain (30). In B. 
cenocepacia, we propose that the Prx activity of BCP fulfils a protective role under 
physiological conditions that precede the induction of these stationary phase anti-oxidants, 
and that this protective role is restricted to the extracellular environment under conditions that 
favour active bacterial replication. It has been established that intracellular B. cenocepacia 
only minimally replicates in macrophages (21, 31). Therefore, it is possible that BcBCP 
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antioxidant activities are physiologically relevant in actively metabolic bacteria, as it has been 
observed for the B. cenocepacia KatA protein that is required for anti-oxidant protection of 
enzymes of TCA cycle (29). How BcBCP activity, and indeed that of other anti-oxidants, 
contributes to the survival of B. cenocepacia within the specific environment of the CF lung is 
unclear. Intriguingly, Pseudomonas aeruginosa isolates from CF infants show reduced 
expression of bcp relative to that observed in the wound isolate, and common laboratory 
strain, PAO1 (RK Ernst; Personal Communication). Furthermore, loss of the related anti-
oxidant AhpC in B. cenocepacia has been associated with the ability to establish persistent 
pulmonary infection in a murine host (30). This latter observation suggests that Burkholderia 
AhpC may be immunogenic, as has been observed for Salmonella typhimurium AhpC (32).  
The immunogenicity of BCP has yet to be addressed, and further studies are required to 
establish the role that these bacterial anti-oxidants play in the adaptation to CF airways. 
In conclusion, we have described a novel Prx enzyme of Burkholderia, and characterized its 
catalytic activity. Although BcBCP does not appear to play a pivotal role in the intracellular 
survival of B. cenocepacia, it confers resistance to ROS at a time when other known anti-
oxidant mediators are not expressed, or expressed only at a low level. Whilst homologous to 
the previously described atypical 2-Cys BCP peroxidase of E. coli, the Burkholderia enzyme 
lacks the resolving cysteine and functions via a 1-Cys peroxidatic mechanism utilising an 
external small molecule thiol redox partner, glutathione, to resolve the oxidized peroxidatic 
cysteine. The resulting glutathionylated-BcBCP intermediate is subsequently reduced by 
glutaredoxin.  These studies provide the first detailed characterization of the 1-Cys Prx 
pathway in a BCP, and highlight the mechanistic differences that exist within the BCP family 
of bacterial peroxiredoxins and support their subdivision into two classes based on their 
catalytic activity. 
SUPPORTING INFORMATION AVAILABLE 
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Top-down fragmentation of H2O2-treated WT BcBCP, NEM-modified WT BcBCP and NEM-
modified L49C BcBCP. MS analysis of the reduction of BcBCP-GSH heterodimer by 
thioredoxin. MS analysis of the reduction of oxidized BcBCP L49C by glutaredoxin and 
thioredoxin. Quantitative RT-PCR analysis of bcp expression. Complementation of BCP-
deficient B. cenocepacia XOA14 with WT BcBCP. Phylogenetic tree of bacterial BCP 
homologues. Amino acid alignments of representative BCP homologues with and without the 
resolving cysteine. This material is available free of charge via the Internet at 
http://pubs.acs.org.
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TABLE 1. Strains and plasmids 
Strain or plasmid Relevant characteristics Source and/or 
reference 
B. cenocepacia 
 
  
K56-2 ET12 clone related to genome sequence strain, 
    
BCCM; (33) 
XOA14 K56-2, bcp::pGPΩTp, Tpr (7) 
ARB201 XOA14, pARB10 (encoding a functional BcBCP 
protein), Tpr, Tetr 
This study 
E. coli strains   
DH5α F- Φ80dlacZΔM15 Δ(lacZYA-argF)U169 recA1 
endA1 hsdR17(rk-, mk+) phoA supE44 λ- thi-1 
gyrA96 relA1 
Invitrogen 
BL21(DE3) F- ompT hsdSB(rB– mB–) gal dcm (DE3) Novagen 
Plasmids   
pET-28a oripBR322, Kanr, PT7lac Novagen 
pDA17 oripBBR1, Tetr, mob+, Pdhfr D. Aubert 
pARB1 pET28a encoding WT BcBCP This study 
pARB2 pET28a encoding C44S BcBCP This study 
pARB3 pET28a encoding C98S BcBCP This study 
pARB4 pET28a encoding L49C BcBCP This study 
pARB5 pET28a encoding WT EcBCP (3) 
pARB10 pDA17 encoding WT BcBCP This study 
 
Tpr, trimethoprim resistance; Tetr, tetracycline resistance; Kanr, kanamycin resistance; 
BCCM, Belgian Co-ordinated Collection of Micro-organisms. 
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FIGURE LEGENDS 
Figure 1. Thiol-dependent peroxidase activity of BcBCP using thioredoxin as the 
reducing partner. The thioredoxin linked peroxidase activity of recombinant BCP proteins 
was assessed in an assay coupled to the oxidation of NADPH (monitored by a decrease in 
A340nm) and measured in µM NADPH oxidized per min per µM of enzyme (µMmin-1µM-1). 
The assay contained 0.36 µM TrxR, 1.7 µM Trx, 0.1 mM H2O2 and 0.2 mM NADPH in 50 
mM Hepes-NaOH (pH 7). ‘+GSH’ indicated the presence of 1 mM reduced GSH in the 
reaction mixture. In the absence of BCP, a background (B/ground) level of NADPH oxidation 
occurs, equating to 0.1 µMmin-1. Enzyme activity is stated as the mean of three independent 
results and the error bars indicate one standard deviation.  
Figure 2. Mass spectrometry analysis of BcBCP and H2O2-treated BcBCP. BcBCP was 
analysed by ESI-FT-ICR MS in  H2O:MeOH:HCOOH (v/v/v 50:48:2) at a final concentration 
of 10 µM. (A, insert) A typical spectrum of BcBCP displaying a charge state distribution from 
[M+11H]11+ to [M+23H]23+ and an average deconvoluted mass of 18992 Da. (A) The most 
abundant ion, [M+17H]17+, has an isotope distribution consistent with a theoretical isotope 
distribution of BcBCP containing 2 reduced cysteine residues (red circles; empirical formula 
[C849H1358N239O246S5]17+). (B) BcBCP after addition of 500 µM H2O2. The isotope distribution 
of the [M+17H]17+ ion reveals a mass shift of +32 Da, to an average mass of 19024 Da, which 
is consistent with the addition of 2 oxygen atoms, attributed to oxidation of cysteine to 
sulfinic acid (blue circles, empirical formula [C849H1358N239O248S5]17+). (C) Prosight-PTM 
output file (cleavage map) showing the top-down fragmentation of sulfinic acid-modified 
BcBCP. ECD of H2O2-treated BcBCP allowed the modification to be mapped to a 3-amino 
acid section containing Cys-44 (see also Supporting Information Figure S1).  
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Figure 3. Amino acid alignment of B. cenocepacia and E. coli BCP. BcBCP and EcBCP 
enzymes have two cysteine residues in common (black arrowheads), at positions Cys-44 and 
Cys-98 (B. cenocepacia co-ordinates). EcBCP has an additional cysteine at Cys-50 (grey 
arrowhead) that is not conserved in the Burkholderia enzyme. Both amino acid sequences are 
shown without the N-terminal methionine, which was cleaved from all purified BCP proteins 
studied.  
Figure 4. Glutathione can act as a resolving-thiol in BcBCP catalysis. BcBCP was 
analysed by ESI-FT-ICR MS in  H2O:MeOH:HCOOH (v/v/v 50:48:2) at a final concentration 
of 10 µM. (A) Typical mass spectrum of BcBCP in the presence of 1mM GSH. The isotope 
distribution of the [M+19H]19+ charge state is consistent with BcBCP containing two reduced 
cysteine residues (red circles; empirical formula [C849H1360N239O246S5]19+), average 
deconvoluted mass 18992 Da. For comparison, the theoretical isotope distribution of BcBCP 
containing one disulfide bond ([C849H1358N239O246S5]19+), is shown in green circles. (B) 
Addition of 1 molar equivalent of H2O2 resulted in a second species of average mass 19297 
Da (∆mass +305 Da). This species displays an isotope distribution consistent with BcBCP 
containing one reduced cysteine and one glutathionylated cysteine (claret circles, empirical 
formula [C859H1375N242O252S6]19+). (C) This species was subsequently derivatized with the 
alkylating agent NEM and reduced with DTT before top-down fragmentation using CID. The 
Prosight-PTM output file (cleavage map) shows the assignment of the NEM modification to 
Cys-98 allowing the assignment of the glutathionylated cysteine to Cys-44 (see also 
Supporting Information Figure S2).  
Figure 5. Analysis of potential reductive partners for BcBCP catalysis using mass 
spectrometry. Glutaredoxin can efficiently reduce glutathionylated BcBCP.  An 
equimolar mixture of BcBCP-GSH and reduced Grx was incubated at room temperature for 2 
min before being quenched with H2O:MeOH:HCOOH (v/v/v 50:48:2). The resulting mixture 
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was analyzed by FT-ICR MS at a final protein concentration of 10 µM. (A) Analysis of the 
isotope distributions of BcBCP-GSH and Grx before mixing. BcBCP-GSH displays an isotope 
distribution consistent with the glutathionylated protein (claret circles; 
[C859H1375N242O252S6]19+). The [M+9H]9+ charge state of the glutaredoxin species displayed an 
isotope distribution consistent with reduced Grx (red circles; [C429H671N116O134S3]9+). The 
theoretical isotope distribution of oxidized Grx is shown in green circles for comparison 
([C429H669N116O134S3]9+). (B) Analysis of the isotope distributions of BcBCP and Grx after 
mixing. The BcBCP species displays an isotope distribution consistent with the reduced 
protein, indicating loss of the GSH moiety (red circles; [C849H1360N239O246S5]19+). The 
[M+9H]9+ charge state of the glutaredoxin species displayed an isotope distribution consistent 
with oxidised Grx (green circles; [C429H669N116O134S3]9+) consistent with the formation of a 
disulfide bond. (C) Broad-band mass spectrum showing the charge state distributions of 
reduced BcBCP and oxidized Grx. BCP charge states are indicated by red squares; Grx charge 
states are indicated by green triangles.  
Figure 6. Peroxidase activity of BCP enzymes using glutaredoxin as the reducing 
partner. The GSH/glutaredoxin linked peroxidase activities of recombinant BCP proteins 
were assessed in an assay coupled to the oxidation of NADPH (monitored by a decrease in 
A340nm) and measured in µM NADPH oxidized per min per µM of enzyme (µMmin-1µM-1). 
The assay contained 1 unit glutathione reductase, 12 µM Grx, 1mM GSH, 0.1 mM hydrogen 
peroxide and 0.15 mM NADPH in 50 mM Hepes-NaOH (pH 7). Enzyme activity is stated as 
the mean of three independent results and the error bars indicate one standard deviation. 
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Figure 7. Introduction of a resolving cysteine (L49C) converts BcBCP from a 1-Cys Prx 
to an atypical 2-Cys Prx.  BcBCP L49C was analysed by ESI-FT-ICR MS in  
H2O:MeOH:HCOOH (v/v/v 50:48:2) at a final concentration of 10 µM. (A) Typical mass 
spectrum of L49C BcBCP displaying a charge state distribution from [M+8H]8+ to 
[M+21H]21+ and an average mass of 18982 Da. Analysis of the isotope distribution of the 
[M+19H]19+ charge state reveals a distribution consistent with L49C BcBCP containing three 
reduced cysteines (red circles; empirical formula [C846 H1354 N239 O246 S6]19+). (B) Mass 
spectrum of L49C BcBCP after addition of 1 molar equivalent of H2O2, in the presence of 
1mM GSH, displays a charge state distribution from [M+8H]8+ to [M+17H]23+. The isotope 
distribution of the [M+19H]19+ reveals a ∆mass of -2 Da and is consistent with L49C BcBCP 
containing one disulfide bond and one reduced cysteine (green circles; empirical formula 
[C846 H1352 N239 O246 S6]19+). (C) H2O2-treated L49C BcBCP was subsequently derivatized 
with the alkylating agent NEM and reduced with DTT before top-down fragmentation using 
ECD. The Prosight-PTM output file (cleavage map) shows the assignment of the NEM 
modification to Cys-98 allowing the assignment of the disulfide bond to Cys-44 and Cys-49 
(see also Supporting Information Figure S4).  
Figure 8. Genetic linkage of bcp in the genus Burkholderia. Within β-proteobacteria that 
exhibit innate resistance to cationic antimicrobial peptides (Burkholderia species and 
organisms of the Ralstonia pickettii group) bcp (black arrow) is located immediately 
downstream of the arn locus (grey arrows). The flanking genes BCAL1928 and BCAL1937 
(white arrows) encode a hypothetical protein and a PhoH-like protein respectively. ‘BCAL’ 
gene nomenclature refers to the genome sequence of B. cenocepacia J2315, chromosome 1.  
Figure 9: Growth-phase dependent role of BcBCP in protecting against oxidative stress. 
At regular intervals throughout the growth phase, percentage survival of B. cenocepacia K56-
2 and the BCP-deficient strain XOA14 was assessed following challenge of each strain with 1 
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mM H2O2 for 30 min. Both K56-2 and XOA14 showed comparable growth in aerobic 
conditions (closed squares and closed circles respectively). XOA14 is hypersensitive to H2O2-
mediated killing at lag phase / early log phase of growth (open circles), compared to K56-2 
(open squares). At stationary phase, both strains are equally resistant to H2O2-mediated 
killing. 
Figure 10: Comparison of intracellular survival and localization within murine 
macrophages of B. cenocepacia K56-2 and the BCP-deficient XOA14. Macrophage 
infection assays demonstrate that Burkholderia BCP is not required for intracellular survival. 
(A) Intracellular survival of early log phase B. cenocepacia K56-2 (grey bars) and XOA14 
(white bars) was quantified 2 h and 4 h postinfection (MOI 50). The BCP-deficient XOA14 is 
not impaired in intracellular survival at early log phase relative to K56-2. (B) The number of 
B. cenocepacia-containing vacuoles (BcCVs) colocalizing with either TMR-Dextran (dex) or 
LysoTracker Red (Lys) was compared following either 2 h or 4 h infection of murine 
macrophages (ANA1 or Raw264.7) with stationary phase K56-2 (grey bars, ‘K’) or XOA14 
(white bars, ‘X’). The number of BcCVs colocalizing with TMR-dextran or LysoTracker Red 
is not significantly different when comparing the two strains, indicating that the stationary 
phase BCP-deficient XOA14 is not impaired in its ability to persist within macrophages. 
Figure 11: Schematic of the peroxidatic mechanisms of 1-Cys and atypical 2-Cys BCPs. 
(A) Catalytic mechanism of a 1-Cys BCP, as exemplified by wildtype BcBCP. The enzyme 
functions via a GSH/Grx dependent 1-Cys Prx mechanism.  In the presence of peroxide, the 
peroxidatic cysteine (Cys-44) is oxidized to a sulfenic acid intermediate. In the absence of a 
small molecule thiol, this sulfenic acid intermediate is irreversibly oxidized to sulfinic acid. 
However, in the presence of glutathione (GSH), a BcBCP-GSH heterodimer is formed, which 
is subsequently resolved by reduced glutaredoxin. (B) Catalytic mechanism of an atypical 2-
Cys BCP, as exemplified by L49C BcBCP or EcBCP. The peroxidatic cysteine is oxidized to 
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the sulfenic acid intermediate prior to disulfide bond formation with the resolving cysteine 
(Cys-49). The formation of this intramolecular disulfide bond is highly favoured, occurring 
even in the presence of excess GSH. The disulfide bridge between Cys-44 and Cys-49 can be 
resolved by the Trx/TrxR redox system. 
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Figure 1. Thiol-dependent peroxidase activity of BcBCP using thioredoxin as the 
reducing partner.  
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Figure 2. Mass spectrometry analysis of BcBCP and H2O2-treated BcBCP. 
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Figure 3: Amino acid alignment of B. cenocepacia and E. coli BCP. 
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Figure 4. Glutathione can act as a resolving-thiol in BcBCP catalysis. 
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Figure 5. Analysis of potential reductive partners for BcBCP catalysis using mass 
spectrometry. Glutaredoxin can efficiently reduce glutathionylated BcBCP.   
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Figure 6. Peroxidase activity of BCP enzymes using glutaredoxin as the reducing 
partner.  
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Figure 7. Introduction of a resolving cysteine (L49C) converts BcBCP from a 1-Cys Prx 
to an atypical 2-Cys Prx.   
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Figure 8: Genetic linkage of bcp in the genus Burkholderia. 
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Figure 9: Growth-phase dependent role of BcBCP in protecting against oxidative stress. 
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Figure 10: Comparison of intracellular survival and localization within murine 
macrophages of B. cenocepacia K56-2 and the BCP-deficient XOA14. 
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Figure 11. Schematic of the peroxidatic mechanisms of 1-Cys and atypical 2-Cys BCPs. 
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